New drug aims to fight skin cancer in transplant patients

NCT ID NCT07100925

Terminated Disease control Sponsor: Ankyra Therapeutics, Inc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study was designed to test a drug called tolododekin alfa (ANK-101) given before surgery to kidney transplant recipients with high-risk skin cancer. The goal was to see if the drug could reduce the number of cancer cells in the removed tissue. However, the trial was withdrawn before any patients were enrolled, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tolododekin alfa (ANK-101)
What this could lead to: If it works, this could point toward a treatment that helps kidney transplant patients with high-risk skin cancer respond better to surgery.
What could go wrong: This trial was withdrawn before any participants were enrolled, so there is no data yet. It is a very early Phase 1 study, and the approach may not prove effective or safe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer skin squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) RENAL TRANSPLANT SOLID TUMOR SOLID TUMOR CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.